Ex vivo studies of [123I]PARPi, a potential PARP SPECT imaging agent, showed high specificity to PARP1 (23), while [131I]PARPi showed the potential as a PARP PET imaging agent for brain tumors (24). Here, PARP1 is linked to brain neoplasm.